结直肠癌早筛：厂商角逐前沿阵地，多维优势赋能行业腾飞 头豹词条报告系列

Investment Rating - The report does not explicitly state an investment rating for the colorectal cancer early screening industry Core Insights - The colorectal cancer early screening industry utilizes advanced technologies to screen high-risk populations, significantly reducing incidence and mortality rates. The primary screening targets are individuals aged 40-74 due to dietary habits and lower average onset age in China. The industry is characterized by technological innovation and strong policy support, with market demand growing alongside rising incidence rates and increased public health awareness. Non-invasive tests like FIT and FIT-DNA are gaining popularity due to their simplicity and high sensitivity, while the aging population and updated screening guidelines are expected to drive significant market expansion in the future [5][6][13][39]. Summary by Sections Industry Definition - Colorectal cancer is defined as cancer occurring in the colon or rectum, with major risk factors including age, family history, and urban lifestyle. The early screening industry focuses on using fecal occult blood tests and fecal genetic testing to identify high-risk individuals for early detection, aiming to reduce the risk of onset and mortality [6][8]. Industry Classification - Screening products are classified based on technology, including colonoscopy, fecal occult blood tests, fecal cell and genetic testing, and multi-omics testing [7][8]. Industry Characteristics - The industry is marked by outstanding technological innovation, high policy support, and strong market demand. The development of high-sensitivity products, particularly in fecal DNA testing, has significantly improved early detection capabilities [13][14][16][17]. Development History - The industry has rapidly developed in China, with significant milestones including the initiation of free screening services in Shanghai in 2003 and the establishment of national guidelines in 2021. The introduction of high NPV fecal DNA testing products has further propelled standardization and technological advancement [18][21]. Industry Chain Analysis - The industry chain consists of upstream suppliers providing raw materials and equipment, midstream manufacturers developing and producing screening products, and downstream consumers including hospitals and testing centers. Upstream cost pressures and downstream market challenges coexist, with manufacturers needing to enhance technological innovation and diversify channels to improve bargaining power [22][23][24]. Market Size - The colorectal cancer early screening market size grew from 5.069 billion RMB in 2018 to 9.759 billion RMB in 2023, with a CAGR of 14.00%. It is projected to reach 27.677 billion RMB by 2028, with a CAGR of 24.75% [36][37]. Competitive Landscape - The market is led by companies like NuoHui Health and KangLiMing Bio, with a strong competitive dynamic. The differentiation in product positioning and pricing strategies is crucial for capturing market share. The trend of decreasing prices for screening products is expected to drive market expansion [43][44][47][48].